CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
B-cell acute lymphoblastic leukemia
blinatumomab
brexucabtagene autoleucel
cytokine release syndrome
immune effector cell-associated neurotoxicity syndrome
tisagenlecleucel
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
25
06
2023
revised:
22
10
2023
accepted:
27
10
2023
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
B-cell acute lymphoblastic leukemia (B-ALL) is the most common subtype of acute leukemia in the pediatric population. The prognosis and treatment of B-ALL have dramatically improved over the past decade with the adoption of intensive and prolonged combination chemotherapy regimens. The advent of novel immunologic agents such as blinatumomab and inotuzumab has changed the treatment landscape of B-ALL. However, patients have continued to relapse, raising the need for novel therapies. Chimeric antigen receptor (CAR) T-cells have achieved a milestone in the treatment of B-ALL. Two CD19-targeting CAR T-cells were approved by the Food and Drug Administration and the European Medicines Agency for the treatment of relapsed and/or refractory B-ALL. In this review, we review the available data regarding CD19-targeting CAR T-cells with their safety profile as well as the mechanism of resistance to these agents and the way to overcome this resistance.
Identifiants
pubmed: 37959347
pii: jcm12216883
doi: 10.3390/jcm12216883
pmc: PMC10647582
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Clin Oncol. 2016 Jul 10;34(20):2380-8
pubmed: 27114587
Nat Med. 2018 Jan;24(1):20-28
pubmed: 29155426
Blood. 2019 Dec 26;134(26):2361-2368
pubmed: 31650176
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):1-6
pubmed: 34889387
Leukemia. 2010 Feb;24(2):265-84
pubmed: 20010625
Ann Oncol. 2022 Mar;33(3):259-275
pubmed: 34923107
Nat Commun. 2020 Nov 23;11(1):5928
pubmed: 33230103
J Clin Oncol. 2010 Aug 20;28(24):3880-9
pubmed: 20660823
Blood. 2018 Apr 5;131(14):1522-1531
pubmed: 29358182
Lancet. 2020 Dec 12;396(10266):1885-1894
pubmed: 33308471
Transplant Cell Ther. 2022 Jan;28(1):21-29
pubmed: 34644605
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Lancet. 2021 Jul 24;398(10297):314-324
pubmed: 34175021
J Clin Oncol. 2023 Mar 20;41(9):1664-1669
pubmed: 36399695
Leukemia. 2018 Nov;32(11):2316-2325
pubmed: 29728694
Nat Commun. 2021 Feb 8;12(1):865
pubmed: 33558546
J Clin Oncol. 2012 May 10;30(14):1663-9
pubmed: 22412151
Nat Med. 2021 Oct;27(10):1797-1805
pubmed: 34642489
J Clin Oncol. 2021 Mar 10;39(8):920-930
pubmed: 33417474
N Engl J Med. 2017 Mar 2;376(9):836-847
pubmed: 28249141
CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103
pubmed: 24488779
Blood. 2017 Jun 22;129(25):3322-3331
pubmed: 28408462
Lancet Haematol. 2020 Nov;7(11):e816-e826
pubmed: 33091355
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Clin Cancer Res. 2018 Dec 15;24(24):6175-6184
pubmed: 30190371
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
Blood. 2021 Jul 8;138(1):11-22
pubmed: 33827116
Lancet Haematol. 2021 Oct;8(10):e711-e722
pubmed: 34560014
Blood. 2019 Apr 11;133(15):1652-1663
pubmed: 30728140
Blood Adv. 2019 Nov 26;3(22):3539-3549
pubmed: 31738832
Leukemia. 2010 Feb;24(2):345-54
pubmed: 20010622
Blood. 2022 Jul 7;140(1):38-44
pubmed: 35421218
J Clin Oncol. 2021 Oct 20;39(30):3352-3363
pubmed: 34464155
Nat Med. 2018 Oct;24(10):1504-1506
pubmed: 30275569
Front Immunol. 2022 Jan 07;12:731435
pubmed: 35069522
J Clin Oncol. 2022 Mar 20;40(9):945-955
pubmed: 34882493
J Clin Oncol. 2022 Mar 20;40(9):932-944
pubmed: 34767461
Nat Commun. 2016 Jul 27;7:12320
pubmed: 27460500
Lancet. 2021 Aug 7;398(10299):491-502
pubmed: 34097852
J Clin Oncol. 2020 Feb 10;38(5):415-422
pubmed: 31815579
Biol Blood Marrow Transplant. 2020 Nov;26(11):e280-e285
pubmed: 32755637
J Clin Oncol. 2023 Jan 10;41(2):354-363
pubmed: 36108252
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
N Engl J Med. 2016 Aug 25;375(8):740-53
pubmed: 27292104
J Clin Oncol. 2010 Feb 1;28(4):648-54
pubmed: 19841326
J Clin Oncol. 2010 Aug 10;28(23):3730-8
pubmed: 20625136
J Hematol Oncol. 2020 May 4;13(1):42
pubmed: 32366260
Pediatr Rheumatol Online J. 2019 Feb 14;17(1):7
pubmed: 30764840
J Clin Oncol. 2008 Mar 20;26(9):1496-503
pubmed: 18349402
Transplant Cell Ther. 2022 Feb;28(2):72.e1-72.e8
pubmed: 34852305
Leukemia. 2019 Dec;33(12):2854-2866
pubmed: 31110217
Nat Med. 2021 Aug;27(8):1419-1431
pubmed: 34312556
Nat Rev Clin Oncol. 2019 Jun;16(6):372-385
pubmed: 30837712
Blood. 2022 Aug 4;140(5):451-463
pubmed: 35605184
Blood Adv. 2023 Jun 27;7(12):2872-2883
pubmed: 36724512
Leukemia. 2021 Nov;35(11):3268-3271
pubmed: 33686196
J Clin Oncol. 2023 Mar 20;41(9):1670-1683
pubmed: 36346962
Blood. 2020 Oct 8;136(15):1786-1789
pubmed: 32492706
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Blood. 2020 Jan 30;135(5):387-391
pubmed: 31725148
Blood Adv. 2022 Jan 25;6(2):600-610
pubmed: 34794180
J Clin Oncol. 2021 May 20;39(15):1650-1659
pubmed: 33764809
Leukemia. 2022 Jun;36(6):1525-1532
pubmed: 35468946
Cancer Discov. 2020 Apr;10(4):552-567
pubmed: 32001516
Ann Oncol. 2016 Sep;27(suppl 5):v69-v82
pubmed: 27056999
J Clin Oncol. 2020 Jun 10;38(17):1938-1950
pubmed: 32286905
Blood. 2019 Apr 4;133(14):1548-1559
pubmed: 30658992
Cancer Discov. 2017 Dec;7(12):1404-1419
pubmed: 29025771
Blood. 2022 Jun 9;139(23):3376-3386
pubmed: 35338773
J Hematol Oncol. 2020 Apr 3;13(1):30
pubmed: 32245502
Am J Hematol. 2019 Oct;94(10):1113-1122
pubmed: 31321805
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
Clin Adv Hematol Oncol. 2019 Mar;17(3):166-175
pubmed: 30969955
J Immunother Cancer. 2021 Aug;9(8):
pubmed: 34353848
Blood. 2020 Jan 2;135(1):17-27
pubmed: 31697824
Blood Adv. 2022 Apr 12;6(7):1969-1976
pubmed: 35134115
J Clin Oncol. 2021 Sep 20;39(27):3044-3055
pubmed: 34156874
Blood Adv. 2020 Nov 10;4(21):5414-5424
pubmed: 33147337
Lancet. 2020 Apr 4;395(10230):1146-1162
pubmed: 32247396